Synonym
UNII-VNC65MEX24; Ciclotropium bromide; Cyclotropium
IUPAC/Chemical Name
(8r)-3alpha-Hydroxy-8-isopropyl-1alphaH,5alphaH-tropanium bromide, alpha-phenylcyclopentaneacetate
InChi Key
SWIGQYOLBLSIAA-BPVFESEESA-M
InChi Code
InChI=1S/C13H16O2.C11H22NO.BrH/c14-13(15)12(11-8-4-5-9-11)10-6-2-1-3-7-10;1-8(2)12(3)9-4-5-10(12)7-11(13)6-9;/h1-3,6-7,11-12H,4-5,8-9H2,(H,14,15);8-11,13H,4-7H2,1-3H3;1H/q;+1;/p-1/t;9-,10+,11-,12+;
SMILES Code
[H][C@]12C[C@@H](O)C[C@](CC1)([N@+]2(C(C)C)C)[H].O=C(O)C(C3=CC=CC=C3)C4CCCC4.[Br-]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
468.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1.Effects of the new vagolytic compound ciclotropium bromide on heart rate and atrial vulnerability.
Heuer H, Frenking B, Thale J, Gülker H, Müller US, Bender F.
Arzneimittelforschung. 1986 Oct;36(10):1451-4.
PMID: 2434105
2.OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1).
Glube N, Closs E, Langguth P.
Mol Pharm. 2007 Jan-Feb;4(1):160-8. doi: 10.1021/mp060073a.
PMID: 17274673
3.[Effect of ciclotropium bromide on pressure in the human common bile duct].
Brandstätter G, Kratochvil P, Stupnicki T, Zenker G.
Arzneimittelforschung. 1983;33(12):1691-3.
PMID: 6686777 German.
4.[Double-blind study of the effect of cyclotropium bromide on the smooth musculature of the esophagus. Description of a test of spasmolytic action].
Lepsien G, Buck W.
Arzneimittelforschung. 1988 Jul;38(7):927-31.
PMID: 3207438 Clinical Trial. German.
5.Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay.
Liebmann B, Mayer S, Mutschler E, Spahn-Langguth H.
Arzneimittelforschung. 1992 Nov;42(11):1354-8.
PMID: 1492851
6.Determination of the quaternary compound ciclotropium in human biological material after hydrolysis and derivatization with the fluorophor flunoxaprofen chloride.
Liebmann B, Henke D, Spahn-Langguth H, Mutschler E.
J Chromatogr. 1991 Dec 6;572(1-2):181-93. doi: 10.1016/0378-4347(91)80482-r.
PMID: 1818053
7.The effect of ciclotropium on human heart rate.
Ding RW, Port RE, Ortmann K, Liebmann B, Spahn-Langguth H, Mutschler E, Weber E.
Eur J Clin Pharmacol. 1994;46(5):455-9. doi: 10.1007/BF00191911.
PMID: 7957543 Clinical Trial.
8.Effects of oral cyclotropium bromide, hyoscine N-butylbromide and placebo on gastric emptying and antral motor activity in healthy man.
Stacher G, Bergmann H, Havlik E, Schmierer G, Schneider C.
Gut. 1984 May;25(5):485-90. doi: 10.1136/gut.25.5.485.
PMID: 6714792 Free PMC article. Clinical Trial.
